MX2024006812A - Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos. - Google Patents

Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos.

Info

Publication number
MX2024006812A
MX2024006812A MX2024006812A MX2024006812A MX2024006812A MX 2024006812 A MX2024006812 A MX 2024006812A MX 2024006812 A MX2024006812 A MX 2024006812A MX 2024006812 A MX2024006812 A MX 2024006812A MX 2024006812 A MX2024006812 A MX 2024006812A
Authority
MX
Mexico
Prior art keywords
npr1
antibodies
methods
antagonist anti
bind
Prior art date
Application number
MX2024006812A
Other languages
English (en)
Spanish (es)
Inventor
Michael Dunn
Lori Morton
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024006812A publication Critical patent/MX2024006812A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024006812A 2021-12-06 2022-12-06 Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos. MX2024006812A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163286476P 2021-12-06 2021-12-06
US202263310078P 2022-02-14 2022-02-14
PCT/US2022/081031 WO2023107957A1 (en) 2021-12-06 2022-12-06 Antagonist anti-npr1 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2024006812A true MX2024006812A (es) 2024-08-19

Family

ID=85017755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006812A MX2024006812A (es) 2021-12-06 2022-12-06 Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos.

Country Status (11)

Country Link
US (1) US12606618B2 (enExample)
EP (1) EP4444416A1 (enExample)
JP (1) JP2024542823A (enExample)
KR (1) KR20240112973A (enExample)
AU (1) AU2022408149A1 (enExample)
CA (1) CA3239802A1 (enExample)
CL (2) CL2024001632A1 (enExample)
CO (1) CO2024008879A2 (enExample)
IL (1) IL313265A (enExample)
MX (1) MX2024006812A (enExample)
WO (1) WO2023107957A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT2281843T (pt) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004011618A2 (en) 2002-07-29 2004-02-05 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20100310561A1 (en) 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
WO2010065293A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
AU2010273585B2 (en) 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9451770B2 (en) 2012-06-08 2016-09-27 Charles Despres Method of activating immune response in plants
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US9987330B2 (en) * 2013-12-05 2018-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing pruritis by blocking natriuretic polypeptide B
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20190135804A1 (en) 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
CN112020518A (zh) * 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
EP3898700A1 (en) 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
DK3941946T3 (da) * 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
US11066469B2 (en) 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
WO2022155324A1 (en) * 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CN118159290A (zh) 2021-10-11 2024-06-07 瑞泽恩制药公司 通过施用抗npr1抗体来影响血液动力学变化的方法

Also Published As

Publication number Publication date
CL2024001632A1 (es) 2025-03-28
AU2022408149A1 (en) 2024-05-23
JP2024542823A (ja) 2024-11-15
EP4444416A1 (en) 2024-10-16
CL2025002112A1 (es) 2025-10-24
US12606618B2 (en) 2026-04-21
WO2023107957A1 (en) 2023-06-15
IL313265A (en) 2024-08-01
CO2024008879A2 (es) 2024-08-08
US20230250170A1 (en) 2023-08-10
CA3239802A1 (en) 2023-06-15
KR20240112973A (ko) 2024-07-19

Similar Documents

Publication Publication Date Title
MX2024011444A (es) Anticuerpos anti-npr1 y usos de los mismos.
MX2023001726A (es) Anticuerpos anti-c5 y usos de los mismos.
PH12022551650A1 (en) Anti-trem2 antibodies and methods of use thereof
MX2024006812A (es) Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos.
MX2024002158A (es) Anticuerpos anti-ccr8 y usos de estos.
MY202870A (en) Anti-ctla-4 antibodies and uses thereof
MY202133A (en) Anti-sortilin antibodies and methods of use thereof
RU2010138612A (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
MX2022009769A (es) Anticuerpos anti-acvr1 y usos de los mismos.
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
ATE466031T1 (de) Anti-hgf-r-antikörper und deren verwendung
ZA202203460B (en) Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap)
MX2023007023A (es) Proteinas de inmunoglobulina que se unen a agonistas de npr1.
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
CL2023003331A1 (es) Anticuerpos anti-tmprs66 y usos de los mismos.
PH12021550945A1 (en) ANTI-HUMAN Fn14 ANTIBODY
MX2020013894A (es) Anticuerpos anti-factor xii/xiia y usos de los mismos.
MY210262A (en) Btla antibodies
EA201990022A1 (ru) Антитела против c5 и их применение
EA201992335A1 (ru) Антитела против сортилина и способы их применения
TH1601004178A (th) ฮิวเมนแอนติบอดีต่อ pd-1
MA38502A1 (fr) Anticorps monoclonal humain isole ou son fragment de liaison a l’antigene qui se lie specifiquement a la gremlin-1 humaine utile pour le traitement des fibroses, cancers et l'inhibition de l'angiogenese